To determine the hearing response rate at 24 weeks after treatment with bevacizumab for symptomatic vestibular schwannomas (VS) in children and young adults with NF2.
Subjects will be treated with open-label bevacizumab 10 mg/kg every 2
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor.
The researchers are asking patients with NF2 related tumors to be in the study, because their he
To learn more about available clinical trials related to brain and spinal tumors, contact us at firstname.lastname@example.org or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2018 Cincinnati Children's Hospital Medical Center. All rights reserved.